Sep 14 |
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
|
Sep 14 |
Merck Appears Ready To Return To June Highs (Technical Analysis)
|
Sep 13 |
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
|
Sep 13 |
Summit boosts Instil, BioNTech as lead drug beats Merck’s Keytruda
|
Sep 13 |
Merck goes ex dividend Monday
|
Sep 13 |
Investors in Merck (NYSE:MRK) have seen decent returns of 74% over the past three years
|
Sep 12 |
Moderna cites 2025 launch for Merck partnered cancer vaccine: report
|
Sep 12 |
Moderna Cost Cuts Fail to Restore Investor Trust
|
Sep 12 |
Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following p...
|
Sep 12 |
Is Merck & Co., Inc. (MRK) the Best Defensive Stock According to Reddit?
|